Drugs / Fulzerasib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07581912 | Apr 2026 → Dec 2028 expected | colorectal cancer | Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07463677 | Mar 2026 → May 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07492342 | Jan 2026 → Mar 2027 expected | acute myeloid leukemia, KRAS gene mutation, non-small cell lung carcinoma | Jianxing He | Recruiting | No outcome recorded |
| Phase 2 | NCT06936644 | Apr 2025 → Apr 2027 expected | respiratory system cancer | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07601048 Comparator | Jun 2026 → May 2028 expected | — | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fulzerasib | “The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in...” NCT06936644 ↗ |
| Known as | IBI351 | “The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in...” NCT06936644 ↗ |
| Action | Inhibit | “KRAS G12C inhibitor monotherapy” NCT07581912 ↗ |
| Modality | Small molecule | — CHEMBL5314463 ↗ |
| Route | Oral | “600 mg orally twice daily” NCT07492342 ↗ |
| Target | KRAS | “KRAS G12C inhibitor monotherapy” NCT07581912 ↗ |